{"id":15688,"date":"2022-01-28T18:32:03","date_gmt":"2022-01-28T13:02:03","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=15688"},"modified":"2024-09-20T12:35:28","modified_gmt":"2024-09-20T07:05:28","slug":"upcoming-drugs-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases","title":{"rendered":"Evaluating the Upcoming Drugs in Pipeline for Major Autoimmune Diseases"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d04b742fe28\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d04b742fe28\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Ultomiris\" >Ultomiris<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#About_Ultomiris\" >About Ultomiris<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Current_Clinical_Status\" >Current Clinical Status<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Marketed_Indication\" >Marketed Indication<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Deucravacitinib\" >Deucravacitinib<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#About_Deucravacitinib\" >About Deucravacitinib<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Current_Clinical_Status-2\" >Current Clinical Status<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Rinvoq\" >Rinvoq<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#About_Rinvoq\" >About Rinvoq&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Current_Clinical_Status_for_Crohns_Disease\" >Current Clinical Status for Crohn\u2019s Disease&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Current_Clinical_Status_for_Ulcerative_Colitis\" >Current Clinical Status for Ulcerative Colitis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Marketed_Indications\" >Marketed Indications<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Tapinarof\" >Tapinarof<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#About_Tapinarof\" >About Tapinarof<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Current_Clinical_Status-3\" >Current Clinical Status<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#Whats_Next\" >What\u2019s Next?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The autoimmune diseases are frequently incapacitating and, in some circumstances, fatal. There are currently more than <a href=\"https:\/\/www.delveinsight.com\/blog\/immunological-and-autoimmune-disorders\"><strong>80 identified autoimmune disorders<\/strong><\/a>, such as Rheumatoid Arthritis, Crohn&#8217;s Disease, Plaque Psoriasis, Ulcerative Colitis, Myasthenia Gravis, and many more with symptoms ranging from mild to severe. Autoimmune diseases are among the most challenging diseases to study for biopharmaceutical developers. While the specific origins of many ailments are unknown, researchers are developing a better knowledge of probable elements that may be involved. Because of the complexities of these disease biology, it is challenging to develop therapies and organize informative clinical studies. However, researchers have discovered that <a href=\"https:\/\/www.delveinsight.com\/blog\/leading-companies-in-autoimmune-diseases-market\">numerous autoimmune diseases<\/a> can have identical symptoms or affect the same regions of the body. Because of this overlap, researchers are looking at drugs that have already been authorized to treat one autoimmune disease as prospective therapies for other autoimmune disorders. This is why pharma giant AbbVie is evaluating its blockbuster drug Rinvoq for other autoimmune diseases such as Crohn\u2019s Disease and Ulcerative Colitis. Not only AbbVie but Alexion is also testing its lead asset Ultomiris for another autoimmune disease. Here, look at the development stages of these drugs for various autoimmune diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ultomiris\"><span class=\"ez-toc-section\" id=\"Ultomiris\"><\/span><strong>Ultomiris<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Drug Name: <\/strong>Ultomiris<\/p>\n\n\n\n<p><strong>Company: <\/strong>Alexion Pharmaceuticals<\/p>\n\n\n\n<p><strong>Disease: <\/strong>Myasthenia Gravis<\/p>\n\n\n\n<p><strong>Development Phase:<\/strong> Pre-registration<\/p>\n\n\n\n<p><strong>Originator: <\/strong>Alexion Pharmaceuticals<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Complement C5 inhibitors<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Ultomiris\"><\/span><strong>About Ultomiris<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Ultomiris (ravulizumab)<\/strong> is a first and only C5 complement inhibitor with a long half-life, that provides rapid, full, and persistent complement suppression. This immunological drug works by blocking the C5 protein in the terminal complement cascade, which is part of the body&#8217;s immune system. When the complement cascade is triggered in an uncontrolled manner, it over-reacts, causing the body to attack its own healthy cells. Ultomiris is given intravenously every eight weeks or every four weeks in pediatric patients weighing less than 20kg after a loading dose.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Clinical_Status\"><\/span><strong>Current Clinical Status<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The FDA has accepted the supplementary Biologics License Application (sBLA) of <strong>Ultomiris (ravulizumab-cwvz)<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/generalized-myasthenia-gravis\">Generalized Myasthenia Gravis (gMG) treatment<\/a> in adults for Priority Review in December 2021. The FDA has set a PDUFA date in the second quarter of 2022. The sBLA filing in the United States is based on the findings of the <strong>Phase III study<\/strong> of Ultomiris in gMG, which Alexion disclosed in July 2021. The study shows effectiveness as early as Week 1 and sustained for 52 weeks (26 weeks randomized controlled phase + 26 weeks open-label extension). The safety profile of Ultomiris in the study was consistent with that found in Phase III Ultomiris studies in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uraemic Syndrome (aHUS). Ultomiris regulatory filings for the treatment of gMG are also being reviewed by health authorities in the European Union (EU) and Japan.<\/p>\n\n\n\n<p>Furthermore, Ultomiris is also being developed for a second neurological disease, Neuromyelitis Optica Spectrum Disorder, with a potential approval date of late 2023. Ultomiris might be up against <strong>UCB&#8217;s zilucoplan<\/strong>, a peptide-based C5 inhibitor developed for once-daily subcutaneous injection.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Marketed_Indication\"><\/span><strong>Marketed Indication<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Ultomiris is approved in the US for <a href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market\">PNH treatment<\/a> in adults and children (one month of age and older); in Europe, it is approved for adults, children (with a bodyweight of more than 10kg), and adolescents with PNH who experience hemolysis with the clinical signs that indicate a high level of disease activity, and for people who are clinically stable after having been treated with Soliris for at least past six months; further, in Japan, it is approved for PNH treatment in adults. It is also approved for aHUS treatment in the US to prevent complement-mediated thrombotic microangiopathy in adults and children aged one month and up, in the EU for the treatment of adults and children with a bodyweight of at least 10kg with aHUS, and in Japan for <a href=\"https:\/\/www.delveinsight.com\/report-store\/atypical-hemolytic-uremic-syndrome-ahus-market\">aHUS treatment in adults and children<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"700\" height=\"363\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11193858\/Key-Drugs-in-Pipeline-for-Autoimmune-Disease.png\" alt=\"key-drugs-in-pipeline-for-autoimmune-diseases\" class=\"wp-image-16088\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11193858\/Key-Drugs-in-Pipeline-for-Autoimmune-Disease.png 700w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11193858\/Key-Drugs-in-Pipeline-for-Autoimmune-Disease-300x156.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11193858\/Key-Drugs-in-Pipeline-for-Autoimmune-Disease-150x78.png 150w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/><figcaption class=\"wp-element-caption\"><strong>Upcoming Drugs for Various Autoimmune Diseases<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Deucravacitinib\"><\/span><strong>Deucravacitinib<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Drug Name: <\/strong>Deucravacitinib<\/p>\n\n\n\n<p><strong>Company: <\/strong>Bristol-Myers Squibb<\/p>\n\n\n\n<p><strong>Disease:<\/strong> Plaque Psoriasis; Psoriasis<\/p>\n\n\n\n<p><strong>Development Phase: <\/strong>Pre-registration<\/p>\n\n\n\n<p><strong>Originator: <\/strong>Bristol-Myers Squibb<\/p>\n\n\n\n<p><strong>MoA: <\/strong>TYK2 kinase inhibitors<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Deucravacitinib\"><\/span><strong>About Deucravacitinib<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Deucravacitinib is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a novel MoA. Deucravacitinib was developed by Bristol Myers Squibb scientists to specifically target TYK2, therefore reducing signaling of interleukin (IL)-23, IL-12, and Type 1 interferon (IFN), important cytokines implicated in the pathophysiology of a variety of immune-mediated disorders, including Psoriasis, Psoriatic Arthritis, Lupus, and Inflammatory Bowel Disease. Deucravacitinib provides great selectivity by binding to the regulatory domain of TYK2, leading to the allosteric regulation of TYK2 and its downstream activities. At therapeutic levels, deucravacitinib does not inhibit JAK1, JAK2, or JAK3. In addition to <strong>POETYK PSO-1 and POETYK PSO-2,<\/strong> <strong>Bristol Myers Squibb<\/strong> is testing deucravacitinib in three more <strong>Psoriasis Phase 3 trials: POETYK PSO-3 (NCT04167462), POETYK PSO-4 (NCT03924427), and POETYK PSO-LTE<\/strong> <strong>(NCT04036435)<\/strong>. It is not approved for any indication in any country so far.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Clinical_Status-2\"><\/span><strong>Current Clinical Status<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The FDA has accepted the NDA for deucravacitinib to <a href=\"https:\/\/www.delveinsight.com\/report-store\/moderate-to-severe-plaque-psoriasis-pipeline-insight\">treat people with moderate to severe Plaque Psoriasis<\/a>, whereas the EMA approved the Marketing Authorization Application in November 2021. The FDA has set a September 10, 2022 deadline for the Prescription Drug User Fee Act (PDUFA). These new regulatory milestones follow the approval of deucravacitinib by Japan&#8217;s Ministry of Health, Labour, and Welfare to treat people with moderate to severe Plaque Psoriasis, Pustular, and Erythrodermic Psoriasis.<\/p>\n\n\n\n<p>The regulatory submissions of BMS\u2019s immunological drug deucravacitinib are based on the findings from the <strong>pivotal POETYK PSO-1 and POETYK PSO-2 studies<\/strong>, which compared once-daily deucravacitinib to placebo and <strong>Otezla<\/strong> in patients with moderate to severe Plaque Psoriasis. When compared to placebo and Otezla, deucravacitinib revealed significant and clinically relevant improvements in skin clearance, symptom load, and quality of life indicators. Deucravacitinib was well tolerated, with a low incidence of withdrawal owing to side events and no clinically significant laboratory abnormalities. Primary findings were presented at the <strong>American Academy of Dermatology Virtual Meeting<\/strong> <strong>Experience<\/strong> in April 2021, while secondary findings were presented at the <strong>European Academy of Dermatology and Venereology 30th Anniversary Congress<\/strong> in September 2021.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Rinvoq\"><\/span><strong>Rinvoq<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Drug Name: <\/strong>Rinvoq<\/p>\n\n\n\n<p><strong>Company: <\/strong>AbbVie<\/p>\n\n\n\n<p><strong>Disease: <\/strong>Crohn\u2019s Disease; Ulcerative Colitis<\/p>\n\n\n\n<p><strong>Development Phase:<\/strong> Pre-registration (Ulcerative Colitis); Phase III (Crohn\u2019s Disease)<\/p>\n\n\n\n<p><strong>Originator: <\/strong>Abbott Laboratories<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Janus kinase 1 inhibitor<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Rinvoq\"><\/span><strong>About Rinvoq<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Rinvoq <\/strong>is an <strong>AbbVie<\/strong>-discovered and developed selective and reversible JAK inhibitor that is being studied in a variety of immune-mediated inflammatory diseases. Rinvoq inhibited JAK-1 more effectively than JAK-2, JAK-3, and TYK-2 in enzymatic and cellular assays. The importance of inhibiting specific JAK enzymes to therapeutic efficacy is unknown at this time.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/upadacitinib-drug-insight-and-market\"><strong>Rinvoq (upadacitinib)<\/strong><\/a> is being developed for moderate-to-severe Crohn&#8217;s Disease (CD) treatment. Beyond the current treatment arsenal, the drug offers a distinct mechanism of action and a convenient oral route of administration. <strong>AbbVie<\/strong>, in particular, has extensive commercial resources and marketing experience with <a href=\"https:\/\/www.delveinsight.com\/report-store\/adalimumab-biosimilars-insight\"><strong>Humira (adalimumab)<\/strong><\/a>.<strong> <\/strong>The company is positioning Rinvoq as its next-generation product, as Humira will face biosimilar competition in the US in 2023. AbbVie anticipates regulatory submissions for Rinvoq for CD in 2022. Aside from Rinvoq, the only other marketed drug in the same class as <strong>Pfizer&#8217;s Xeljanz (tofacitinib)<\/strong>, which has been on the market in the United States since 2018.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Clinical_Status_for_Crohns_Disease\"><\/span><strong>Current Clinical Status for Crohn\u2019s Disease<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rinvoq, AbbVie&#8217;s blockbuster immunological drug candidate, has won approval in a difficult-to-treat group of Crohn&#8217;s Disease patients, potentially giving the company another arrow in its post-Humira quiver. The immunological drug is currently in Phase III of development and achieved the primary and secondary endpoints in the first Phase III induction <strong>U-EXCEED study,<\/strong> aimed at assessing the efficacy and safety of upadacitinib <strong>45 mg<\/strong> induction <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/crohns-disease-newsletter\">treatment in adults with moderate to severe Crohn&#8217;s Disease<\/a>. U-EXCEED enrolled patients who had a poor response to or intolerance to biologic therapy. The second induction study looked at patients who had an inadequate response or intolerance to one or more conventional and biological treatments.&nbsp;<\/p>\n\n\n\n<p>Furthermore, the U-EXCEED study is divided into three parts. The first phase is a 12-week placebo-controlled induction period. Part 2 of U-EXCEED is an open-label arm evaluating an additional group of patients who received upadacitinib<strong> 45 mg<\/strong> for 12 weeks. Part 3 comprises patients who did not achieve a clinical response in Part 1 or Part 2 received a 12-week extension of upadacitinib <strong>45 mg or 30 mg<\/strong> treatment. The study included slightly different sets of primary and secondary endpoints for the FDA and the EMA.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Clinical_Status_for_Ulcerative_Colitis\"><\/span><strong>Current Clinical Status for Ulcerative Colitis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>AbbVie, on September 2021, submitted applications to the FDA for approval of <strong>upadacitinib (maintenance dose and induction dose)<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market\">moderate to severe Ulcerative Colitis treatment<\/a> in adults, as well as to the EMA for moderate to severe Ulcerative Colitis treatment in adults who have received an inadequate response.&nbsp;<\/p>\n\n\n\n<p>The submission was based on the findings of the three Phase 3 studies, namely <strong>U-ACHIEVE and U-ACCOMPLISH<\/strong>, designed to assess the safety and efficacy of <strong>upadacitinib 45 mg<\/strong> once daily and <strong>upadacitinib 15 mg and 30 mg<\/strong> once daily in subjects with moderate to severe Ulcerative Colitis. The U-ACHIEVE induction study&#8217;s topline results were announced in December 2020, while the U-ACCOMPLISH induction study&#8217;s topline results were announced in February 2021, and the U-ACHIEVE maintenance study&#8217;s topline results were announced in June 2021.<\/p>\n\n\n\n<p><strong>Subscribe to our newsletter series to get more information about the <\/strong><a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/ulcerative-colitis-market\"><strong>Ulcerative Colitis Pipeline Landscape<\/strong><\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Marketed_Indications\"><\/span><strong>Marketed Indications<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Rinvoq 15 mg<\/strong> has been approved by the FDA for the treatment of moderate to severe Rheumatoid Arthritis in individuals who have had a poor response or intolerance to one or more TNF blockers. In the European Union, <strong>Rinvoq 15 mg<\/strong> is approved for moderate to severe Rheumatoid Arthritis, Psoriatic Arthritis, <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/ankylosing-spondylitis-market\">Ankylosing Spondylitis treatment<\/a>, and for adults and adolescents 12 years and older with moderate to severe Atopic Dermatitis. Further, <strong>Rinvoq 30 mg<\/strong> is approved in the EU for adults with moderate to severe Atopic Dermatitis who are under the age of 65.<\/p>\n\n\n\n<p>In addition, Rinvoq will compete with <strong>Gilead\u2019s Jyseleca (filgotinib)<\/strong>, another JAK inhibitor. Jyseleca fared well in Phase II CD clinical trials and is poised to fill a gap in the market by focusing on inadequate responders to biologic and conventional medicines, as well as perianal fistulizing CD.<\/p>\n\n\n\n<p>The benefit or risk profile of the higher <strong>200mg Jyseleca dose<\/strong>, on the other hand, has been called into question by the FDA, threatening the immunological drug&#8217;s success. The JAK inhibitor class has previously been linked to Venous Thromboembolism and Pulmonary Embolism issues, prompting the FDA to reject higher doses of these drugs.<\/p>\n\n\n\n<p>Nonetheless, Rinvoq has already cleared this hurdle, whereas Jyseleca has yet to be approved in the United States for any indication. Rinvoq is expected to be the first-to-market novel JAK inhibitor for CD, providing a competitive advantage over Jyseleca and facilitating uptake.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/upadacitinib-drug-insight-and-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape-1024x256.png\" alt=\"rinvoq-market-landscape\" class=\"wp-image-16090\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194109\/Rinvoq-market-landscape.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tapinarof\"><\/span><strong>Tapinarof<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Drug Name: <\/strong>Tapinarof<\/p>\n\n\n\n<p><strong>Company: <\/strong>Dermavant Sciences<\/p>\n\n\n\n<p><strong>Disease:<\/strong> Plaque Psoriasis<\/p>\n\n\n\n<p><strong>Development Phase: <\/strong>Registered<\/p>\n\n\n\n<p><strong>Originator: <\/strong>Welichem Biotech<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Aryl hydrocarbon receptor agonists<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Tapinarof\"><\/span><strong>About Tapinarof<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Tapinarof is a novel, non-steroidal, topical aryl hydrocarbon receptor-modulating agent whose mode of action is attributed to specific binding and activation of AhR, a ligand-dependent transcription factor, resulting in the down-regulation of pro-inflammatory cytokines, including interleukin 17, and regulation of skin barrier protein expression to promote skin barrier normalization.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Clinical_Status-3\"><\/span><strong>Current Clinical Status<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The FDA has accepted an NDA for tapinarof for <a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\">Plaque Psoriasis treatment<\/a> in adult patients in August 2021 and assigned a Prescription Drug User Fee Act target action date in Q2 2022. Dermavant&#8217;s flagship Phase 3 clinical program for tapinarof in adult Plaque Psoriasis includes <strong>PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), <\/strong>as well as<strong> PSOARING 3 (NCT04053387)<\/strong>, a long-term extension trial. In January 2022, the company announced the findings of a patient satisfaction questionnaire in the long-term, open-label <strong>Phase 3 PSOARING 3 extension trial<\/strong> of tapinarof cream 1% once daily for the treatment of Plaque Psoriasis in adults. Patient responses revealed consistent high levels of satisfaction and positive perception of tapinarof treatment across all patient-relevant parameters, including patient satisfaction with treatment efficacy, formulation elegance, ease of application, impact on daily life, and preference for tapinarof over prior psoriasis therapies. These findings were presented at the <strong>2022 Winter Clinical Dermatology Conference,<\/strong> which took place from January 14 to 19 in Koloa, Hawaii.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Whats_Next\"><\/span><strong>What\u2019s Next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Every year, many scientists and other specialists in the biopharma industry see years of hard work pay off with regulatory approvals. With the <a href=\"https:\/\/www.delveinsight.com\/covid19\">COVID-19 crisis<\/a>, now in its third year, the 2022 batch of new immunological drugs in the pipeline for autoimmune disease shows that the industry has learned how to work in a pandemic. All the therapies in the pipeline, including the blockbuster drugs Rinvoq and Ultomiris, are in the late stage of development for <a href=\"https:\/\/www.delveinsight.com\/blog\/leading-companies-in-autoimmune-diseases-market\">various autoimmune diseases<\/a>. The approval of these drugs will bring a positive ray of hope for many patients suffering from different autoimmune diseases. Furthermore, the rise in the number of geriatric people will allow many pharma companies to develop therapy and create a positive shift in the autoimmune disease market growth in the future.&nbsp;&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1643372865615\"><strong class=\"schema-faq-question\"><strong>1. Which are the drugs in pipeline for autoimmune diseases in 2022?<\/strong><\/strong> <p class=\"schema-faq-answer\"> There are quite a few drugs in the pipeline for autoimmune diseases including the blockbuster drugs Rinvoq and Ultomiris along with the novel entrants Deucravacitinib and Tapinarof. <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1643372893218\"><strong class=\"schema-faq-question\"><strong>2. What are the indications for which the Rinvoq is approved?<\/strong><\/strong> <p class=\"schema-faq-answer\">Rinvoq has been approved by the FDA for the treatment of moderate to severe Rheumatoid Arthritis. In Europe, Rinvoq is approved for moderate to severe Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis treatment, and for adults and adolescents 12 years and older with moderate to severe Atopic Dermatitis.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1643372903680\"><strong class=\"schema-faq-question\"><strong>3. What are the indications for which Ultomiris is approved?<\/strong><\/strong> <p class=\"schema-faq-answer\">Ultomiris is approved in the US for PNH and aHUS treatment in adults and children; in Europe, it is approved for adults, children, and adolescents with PNH and aHUS; further, in Japan, it is approved for PNH treatment in adults and aHUS treatment in adults and children.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1643372926375\"><strong class=\"schema-faq-question\"><strong>4. Which are the companies working in the pipeline for autoimmune diseases?<\/strong><\/strong> <p class=\"schema-faq-answer\">The pharma giant AbbVie is evaluating its blockbuster drug for other autoimmune diseases. In addition, several pharma companies such as Pfizer, BMS, Dermavant Sciences, Alexion, and others are working on their drug candidates to improve the autoimmune diseases treatment outlook.<\/p> <\/div> <\/div>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The autoimmune diseases are frequently incapacitating and, in some circumstances, fatal. There are currently more than 80 identified autoimmune disorders, such as Rheumatoid Arthritis, Crohn&#8217;s Disease, Plaque Psoriasis, Ulcerative Colitis, Myasthenia Gravis, and many more with symptoms ranging from mild to severe. Autoimmune diseases are among the most challenging diseases to study for biopharmaceutical developers. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":15689,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16939,10830,2077,19058,1554,1546,5587,19059,19060,16410,19057],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-15688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-autoimmune-diseases","tag-covid-19","tag-crohns-disease","tag-deucravacitinib","tag-myasthenia-gravis","tag-plaque-psoriasis","tag-psoriasis","tag-rinvoq","tag-tapinarof","tag-ulcerative-colitis","tag-ultomiris","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Key Drugs for Autoimmune Diseases in Pipeline for 2022<\/title>\n<meta name=\"description\" content=\"All the drugs in the pipeline for the 2022 batch for autoimmune disease including Rinvoq and Ultomirus are in the late stage of development\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Key Drugs for Autoimmune Diseases in Pipeline for 2022\" \/>\n<meta property=\"og:description\" content=\"All the drugs in the pipeline for the 2022 batch for autoimmune disease including Rinvoq and Ultomirus are in the late stage of development\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-28T13:02:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-20T07:05:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/28180048\/Watch-out-for-the-Top-Drugs-in-Pipeline-for-Autoimmune-Disease.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Key Drugs for Autoimmune Diseases in Pipeline for 2022","description":"All the drugs in the pipeline for the 2022 batch for autoimmune disease including Rinvoq and Ultomirus are in the late stage of development","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases","og_locale":"en_US","og_type":"article","og_title":"Key Drugs for Autoimmune Diseases in Pipeline for 2022","og_description":"All the drugs in the pipeline for the 2022 batch for autoimmune disease including Rinvoq and Ultomirus are in the late stage of development","og_url":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-01-28T13:02:03+00:00","article_modified_time":"2024-09-20T07:05:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/28180048\/Watch-out-for-the-Top-Drugs-in-Pipeline-for-Autoimmune-Disease.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases","url":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases","name":"Key Drugs for Autoimmune Diseases in Pipeline for 2022","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/28180048\/Watch-out-for-the-Top-Drugs-in-Pipeline-for-Autoimmune-Disease.png","datePublished":"2022-01-28T13:02:03+00:00","dateModified":"2024-09-20T07:05:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"All the drugs in the pipeline for the 2022 batch for autoimmune disease including Rinvoq and Ultomirus are in the late stage of development","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372865615"},{"@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372893218"},{"@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372903680"},{"@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372926375"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/28180048\/Watch-out-for-the-Top-Drugs-in-Pipeline-for-Autoimmune-Disease.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/28180048\/Watch-out-for-the-Top-Drugs-in-Pipeline-for-Autoimmune-Disease.png","width":772,"height":482,"caption":"upcoming-drugs-for-autoimmune-diseases"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372865615","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372865615","name":"1. Which are the drugs in pipeline for autoimmune diseases in 2022?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":" There are quite a few drugs in the pipeline for autoimmune diseases including the blockbuster drugs Rinvoq and Ultomiris along with the novel entrants Deucravacitinib and Tapinarof. ","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372893218","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372893218","name":"2. What are the indications for which the Rinvoq is approved?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Rinvoq has been approved by the FDA for the treatment of moderate to severe Rheumatoid Arthritis. In Europe, Rinvoq is approved for moderate to severe Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis treatment, and for adults and adolescents 12 years and older with moderate to severe Atopic Dermatitis.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372903680","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372903680","name":"3. What are the indications for which Ultomiris is approved?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Ultomiris is approved in the US for PNH and aHUS treatment in adults and children; in Europe, it is approved for adults, children, and adolescents with PNH and aHUS; further, in Japan, it is approved for PNH treatment in adults and aHUS treatment in adults and children.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372926375","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/upcoming-drugs-for-autoimmune-diseases#faq-question-1643372926375","name":"4. Which are the companies working in the pipeline for autoimmune diseases?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The pharma giant AbbVie is evaluating its blockbuster drug for other autoimmune diseases. In addition, several pharma companies such as Pfizer, BMS, Dermavant Sciences, Alexion, and others are working on their drug candidates to improve the autoimmune diseases treatment outlook.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/28180048\/Watch-out-for-the-Top-Drugs-in-Pipeline-for-Autoimmune-Disease-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">autoimmune diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Deucravacitinib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">myasthenia gravis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Plaque Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rinvoq<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tapinarof<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ulcerative colitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ultomiris<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">autoimmune diseases<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Deucravacitinib<\/span>","<span class=\"advgb-post-tax-term\">myasthenia gravis<\/span>","<span class=\"advgb-post-tax-term\">Plaque Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Rinvoq<\/span>","<span class=\"advgb-post-tax-term\">Tapinarof<\/span>","<span class=\"advgb-post-tax-term\">Ulcerative colitis<\/span>","<span class=\"advgb-post-tax-term\">Ultomiris<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jan 28, 2022","modified":"Updated on Sep 20, 2024"},"absolute_dates_time":{"created":"Posted on Jan 28, 2022 6:32 pm","modified":"Updated on Sep 20, 2024 12:35 pm"},"featured_img_caption":"upcoming-drugs-for-autoimmune-diseases","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=15688"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15688\/revisions"}],"predecessor-version":[{"id":29673,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15688\/revisions\/29673"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/15689"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=15688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=15688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=15688"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=15688"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=15688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}